The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index.
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Open accessAbstract
Fungal infections are a major contributor to infectious disease-related deaths across the globe. Candida species are among the most common causes of invasive mycotic disease, with Candida albicans reigning as the leading cause of invasive candidiasis. Given that fungi are eukaryotes like their human host, the number of unique molecular targets that can be exploited for antifungal development remains limited. Currently, there are only three major classes of drugs approved for the treatment of invasive mycoses, and the efficacy of these agents is compromised by the development of drug resistance in pathogen populations. Notably, the emergence of additional drug-resistant species, such as Candida auris and Candida glabrata, further threatens the limited armamentarium of antifungals available to treat these serious infections. Here, we describe our current arsenal of antifungals and elaborate on the resistance mechanisms Candida species possess that render them recalcitrant to therapeutic intervention. Finally, we highlight some of the most promising therapeutic strategies that may help combat antifungal resistance, including combination therapy, targeting fungal-virulence traits, and modulating host immunity. Overall, a thorough understanding of the mechanistic principles governing antifungal drug resistance is fundamental for the development of novel therapeutics to combat current and emerging fungal threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, large-scale genomic alterations, including aneuploidy, loss-of-heterozygosity (LOH), and chromosomal rearrangements, can affect the expression of drug targets, efflux pumps, and other resistance factors (7).”
From Potential role of lysine acetylation in the stepwise adaptation of Candida albicans to fluconazole (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These mutations lead to either the overexpression of the enzyme itself (14) or alterations in its activity that can lower fluconazole’s binding strength, leading to reduced drug effectiveness (15).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [15]
In the citing paper
“the only new class of antifungal drugs developed in decades, the echinocandins, displays negligible antifungal activity against Cryptococcus spp.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [2]
In the citing paper
“Treatment options for invasive cryptococcal infection are limited, given that Cryptococcus spp. are intrinsically resistant to echinocandins and that they employ an arsenal of defences that enable resistance to azoles2,8.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [2]
In the citing paper
“the polyene amphotericin B has been the primary treatment for cryptococcal infection for more than half a century, despite the fact that it causes substantial toxicity and that its availability is limited by economic and logistical constraints2,4”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [2]
In the citing paper
“current antifungal drug treatments for invasive fungal infections are limited to polyenes, azoles and echinocandins2”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [2]
In the citing paper
“Combination therapy has the potential to confer enhanced efficacy and fungal selectivity while reducing vulnerability to the evolution of resistance2.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,455
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555
Flagged first, then by citations
Research works printed but not linked: 1
- Besterman, J.; Nguyen, D. T.; Ste-Croix, H. MGCD290, an Oral Fungal Hos2 Inhibitor, Enhances the Antifungal Properties of Fluconazole Following Multiple-or Single-Dose Oral Administration in Pre-and Post-Infection Settings. In Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ; MethylGene, Inc.: San Francisco, CA, 2012; Vol. Poster M-1711.
Cited by
Sorted by citations
Items 301–400 of 823
Pujari, A. K., Kirar, S., Gogde, K., Rawat, K., & Bhaumik, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00482 · Cited by 9
Meng, L., Li, J., Wang, D., Han, M., Gao, S., Zhang, Y., Zhu, W., & Liu, C. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11445-w · Cited by 10
Kumar, A., Madalambika, BharathKumar, P. M., Patil, P. R., Rangaswamy, J., Ramu, R., Gowda, K. B. V., & Naik, N. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118425 · Cited by 9
Membrane-Targeting Poly(Amino Acids) with a Phage-Like Action Process for Antifungal Therapy
Zhao, X., Wang, S., Yang, J.-Z., Tian, Y., Choonara, Y. E., Wan, P., Xiao, C., & Chen, L. (2025) · ACS Nano · doi:10.1021/acsnano.5c13661 · Cited by 9
Recent Advances in Nanoparticle Formulations for Treating Fungal Diseases
LaMastro, V., & Shukla, A. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510532 · Cited by 10
Mendes, A. G. G., Campos, C. D. L., Filho, J. L. P., Almeida, V. S. S., Moreira, I. V., Marques, R., Silva, M. C. P., & Monteiro‐Neto, V. (2026) · Antibiotics · doi:10.3390/antibiotics15010072 · Cited by 9
Flow Cytometric Measurement of Efflux in Candida Species
Iyer, K. R., Robbins, N., & Cowen, L. E. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.121 · Cited by 9
Self-citationThe SAGA and NuA4 component Tra1 regulates Candida albicans drug resistance and pathogenesis
Razzaq, I., Berg, M. D., Jiang, Y., Genereaux, J. L., Uthayakumar, D., Kim, G. H., Agyare-Tabbi, M. R., Halder, V., Brandl, C. J., Lajoie, P., et al. (2021) · Genetics · doi:10.1093/genetics/iyab131 · Cited by 9
Memariani, M., Memariani, H., Poursafavi, Z., & Baseri, Z. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10401-5 · Cited by 9
Experimental evolution of drug resistance in human fungal pathogens
Gerstein, A. C., & Sethi, P. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101965 · Cited by 9
Wu, Z., Wu, Q., Yuan, W., Chen, Y., Hu, D., Deng, D., Zhang, L.-L., & Niu, X. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04051-22 · Cited by 9
Quinolone-3-amidoalkanol: A New Class of Potent and Broad-Spectrum Antimicrobial Agent
Dube, P. S., Angula, K. T., Legoabe, L. J., Jordaan, A., Zarella, J. M. B., Warner, D. F., Doggett, J. S., & Beteck, R. M. (2023) · ACS Omega · doi:10.1021/acsomega.3c01406 · Cited by 9
Plasma activated Ezhangfeng Cuji as innovative antifungal agent and its inactivation mechanism
Lin, L., Zhuo, Y., Dong, Q., Yang, C., Cheng, C., & Liu, T. (2023) · AMB Express · doi:10.1186/s13568-023-01571-6 · Cited by 10
Ašanin, D. P., Andrejević, T. P., Nenadović, M., Rodić, M. V., Vojnović, S., Djuran, M. I., & Glišić, B. Đ. (2023) · Polyhedron · doi:10.1016/j.poly.2023.116585 · Cited by 9
Exploration of Baicalein-Core Derivatives as Potent Antifungal Agents: SAR and Mechanism Insights
Zhou, H., Yang, N., Li, W., Peng, X., Dong, J.-X., Jiang, Y., Yan, L., Zhang, D., & Jin, Y. (2023) · Molecules · doi:10.3390/molecules28176340 · Cited by 9
Wang, X., Jin, X., Xie, Z., Zhang, H., Liu, T., Zheng, H., Luan, X., Sun, Y., Fang, W., Chang, W., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01068 · Cited by 9
Ji, J., Liang, C.-T., Zhong, J.-J., Kong, X., Xu, H., Xu, C., & Fu, M. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103954 · Cited by 9
Wang, Q., Wang, Z., Xu, C., Wu, D., Wang, T., Wang, C., & Shao, J. (2024) · Medical Mycology · doi:10.1093/mmy/myae014 · Cited by 9
Hsp90-Mediated Multi-Drug Resistance in DNA Polymerase-Defective Strains of Candida albicans
Utkalaja, B. G., Sahu, S. R., Parida, S. S., & Acharya, N. (2024) · Journal of Fungi · doi:10.3390/jof10030222 · Cited by 9
Exploring the Therapeutic Potential of Scorpion-Derived Css54 Peptide Against Candida albicans
Park, J., Kim, H., Kang, D. D., & Park, Y. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00113-4 · Cited by 9
Synthesis and antifungal evaluation of new azole derivatives containing 1,2,3-triazole
Huang, Z., Chen, H., Zhang, X., Wang, R., Hu, C., & Mao, Z. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00724g · Cited by 9
Buonanno, A., Salvatore, M. M., Feola, A., Siciliano, A., Bellavita, R., Imbò, L. E., Guida, M., Andolfi, A., Nicoletti, R., Maione, A., et al. (2024) · Molecules · doi:10.3390/molecules29245949 · Cited by 9
Molecular investigations on Candida glabrata clinical isolates for pharmacological targeting
Gupta, H., Gupta, P., Kairamkonda, M., & Poluri, K. M. (2022) · RSC Advances · doi:10.1039/d2ra02092k · Cited by 9
Sah, S. K., Bhattacharya, S., Yadav, A., Husain, F., Ndiaye, A. B. K. T., Kruppa, M., Hayes, J. J., & Rustchenko, E. P. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00977-22 · Cited by 10
Candida albicans enhances iron uptake to maintain fluconazole resistance
Sharma, R., Nahar, A., & Puri, S. (2025) · Infection and Immunity · doi:10.1128/iai.00002-25 · Cited by 8
Ssa1-targeted antibody prevents host invasion by Candida albicans
Qiu, X.-R., Shen, C.-R., Jiang, L., Ji, P., Zhang, Y., Hou, W.-T., Zhang, W., Shen, H., & An, M. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1182914 · Cited by 10
Ugochukwu, I. C. I., Rhimi, W., Chebil, W., Rizzo, A., Tempesta, M., Giusiano, G., Tábora, R. F. M., Otranto, D., & Cafarchia, C. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2276367 · Cited by 8
Dong, Y., Du, J., Deng, Y., Cheng, M., Shi, Z., Zhu, H., Sun, H., Yu, Q., & Li, M. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127552 · Cited by 8
SarveAhrabi, Y., & Khoei, S. N. (2023) · Journal of Skin and Stem Cell · doi:10.5812/jssc-142360 · Cited by 8
Huanbutta, K., Sriamornsak, P., Chatchaipan, T., Tuntipimonpun, K., Mongkhon, C., Rattanachitthawat, N., Thampithak, A., & Sangnim, T. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100655 · Cited by 8
Dutra, M. D. S., Araújo, P. R. M., da Rocha, M. G., Pereira, V. C., Freitas, A. S., Lopes, R. G. P., Souza, P. F. N., Montenegro, R. C., Pereira‐Neto, W. D. A., Araújo, G. D. S., et al. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001976 · Cited by 8
Fu, X., Zhang, L., Lin, J., Wang, Q., Wang, Z., Chi, M., Li, D., Zhao, G., & Li, C. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s517169 · Cited by 8
Mechanisms of aureobasidin A inhibition and drug resistance in a fungal IPC synthase complex
Wu, X., Gong, X., & Xie, T. (2025) · Nature Communications · doi:10.1038/s41467-025-60423-y · Cited by 8
Effective treatment of systemic candidiasis by synergistic targeting of cell wall synthesis
Chung, J. Y., Hong, Y.-K., Jeon, E., Yang, S., Park, A., Weissleder, R., Chong, Y. P., & Chung, H. J. (2025) · Nature Communications · doi:10.1038/s41467-025-60684-7 · Cited by 8
Design of probiotic-nanozyme synergistic systems: A new bio-hybrid strategy for disease therapy
Dai, C., Liu, Y., Li, W., Gu, Q., Han, J., Ma, C., Liu, X., Ngai, T., Su, J., McClements, D. J., et al. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217228 · Cited by 8
Li, X., Chen, S., Lyu, X., & Tian, J. (2022) · Medical Mycology · doi:10.1093/mmy/myac087 · Cited by 8
Correlation Between Drug Resistance and Virulence of Candida Isolates from Patients with Candidiasis
Yang, Z., Zhang, F., Li, D., Wang, S., Pang, Z., Chen, L., Li, R., & Shi, D. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s387675 · Cited by 8
Cotabarren, J., Ozón, B., Claver, S., Geier, F. R., Rossotti, M., García‐Pardo, J., & Obregón, W. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030781 · Cited by 8
Ajetunmobi, O. H., Chaturvedi, A. K., Badali, H., Vaccaro, A., Najvar, L. K., Wormley, F. L., Wiederhold, N. P., Patterson, T. F., & Lopez-Ribot, J. L. (2023) · Apmis · doi:10.1111/apm.13342 · Cited by 8
Synthesis and antibacterial activities of baulamycin A inspired derivatives
Kim, N., Sengupta, S., Lee, J., Dash, U., Kim, S., Kim, H. J., Song, C., & Sim, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115592 · Cited by 8
Shinohara, T., Wada, A., Abe, M., Nakayama, N., Nagi, M., & Miyazaki, Y. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlad155 · Cited by 8
Lu, G., Ju, X., Zhu, M., Ou, J., Xu, D., Li, K., Jiang, W., Wan, C., Tian, Y., & Niu, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303755 · Cited by 8
Antifungal Activity of Extracts, Fractions, and Constituents from Coccoloba cowellii Leaves
Méndez, D., Arranz, J. C. E., Pérez, E. M., Foubert, K., Matheeussen, A., Tuenter, E., Cuypers, A., Cos, P., & Pieters, L. A. C. (2021) · Pharmaceuticals · doi:10.3390/ph14090917 · Cited by 9
Synthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives
Vaso, C. O., Pandolfi, F., Bila, N. M., Vita, D. D., Bortolami, M., Mendes‐Giannini, M. J. S., Tudino, V., Costi, R., Costa-Orlandi, C. B., Fusco‐Almeida, A. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030593 · Cited by 8
Xu, Y., Shen, Y., Du, C., Liu, L., Wu, H., & Ji, Q. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114723 · Cited by 8
A data library of Candida albicans functional genomic screens
Gervais, N. C., Halder, V., & Shapiro, R. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab060 · Cited by 8
Mechanisms of Antifungal Drug Resistance
Francesconi, F., Jálkh, A. P., Lupi, O., & Khalfe, Y. (2021) · Updates in clinical dermatology · doi:10.1007/978-3-030-68321-4_8 · Cited by 8
Jiang, J. (2023) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-023-10179-y · Cited by 7
Zhang, S., Geng, Y., Wei, B., Lu, Y., He, L., Zhao, F., Zhang, J., Qin, Z., & Gong, J. (2023) · Journal of Fungi · doi:10.3390/jof10010028 · Cited by 7
Santos, M. P. M. C., de Oliveira, L. S., de Lima-Neto, R. G., Andrade, C. A. S., & Oliveira, M. D. L. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116299 · Cited by 7
Andrade-Pavón, D., Gómez‐García, O., & Villa‐Tanaca, L. (2024) · Journal of Fungi · doi:10.3390/jof10090629 · Cited by 10
Ascorbic Acid Enhances the Inhibitory Effect of Theasaponins against Candida albicans
Chen, Y., Gao, Y., & Yin, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910661 · Cited by 7
Improving antifungal lipid-based drug delivery against Candida : a review
Marena, G. D., Gaitán, A. C. R., Bauab, T. M., & Chorilli, M. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2421402 · Cited by 8
Kubera, D., Sławińska-Brych, A., Dróźdż, A., Olender, A., Bogut, A., Matwijczuk, A. P., Karcz, D., Kimsa‐Dudek, M., Gola, J. M., Kruszniewska‐Rajs, C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01075-2 · Cited by 7
Sampedro‐Guerrero, J., Avendaño, V. A., Gómez‐Cadenas, ., & Clausell-Terol, C. (2025) · Powder Technology · doi:10.1016/j.powtec.2025.121141 · Cited by 7
ATR-FTIR spectroscopic markers indicating drug resistance in selected Candida strains
Dróźdż, A., Kubera, D., Olender, A., Dąbrowski, W., Szukała, M., Wośko, S., Chwiej, J. G., Rugiel, M. M., Kawon, K. K., & Gagoś, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-01428-x · Cited by 7
Fifolato, M. A., Clemente, L. M., Ribeiro, A. B., Oliveira, V. D. C., Salgado, H. C., Watanabe, E., & Silva‐Lovato, C. H. (2025) · Microorganisms · doi:10.3390/microorganisms13092057 · Cited by 7
Zhu, Y., Li, T., Zhou, S., Qin, X.-J., Li, Y., Noiprasert, S., Apiwongsrichai, K., Xu, F.-R., Liu, X.-Y., & Dong, X. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04369-7 · Cited by 7
Li, R., Yang, X., Dan, W., & Dai, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118435 · Cited by 7
The pathogenicity and future treatment strategies of Candida albicans
Wu, J., Jiang, C., Wang, H., Chen, T., Chen, X., & Da, W. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1752304 · Cited by 7
Antimicrobial Mechanisms of Enterocin CHQS Against Candida albicans
Wang, Q., Pan, L., Han, Y., & Zhou, Z. (2022) · Current Microbiology · doi:10.1007/s00284-022-02878-6 · Cited by 7
Mohanraj, H., Vinodhini, V. M., & Vajravelu, L. K. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.2.27 · Cited by 7
Yona, A., & Fridman, M. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00595 · Cited by 8
Fonseca, V. J. A., dos Santos, S. C., Carneiro, J. N. P., dos Santos, A. T. L., de Freitas, M. A., de Carvalho, N. K. G., Silva, F. D. S., dos Santos, A. G., Menêses, A. V. S., Farias, N. S., et al. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107242 · Cited by 7
Carneiro, J. N. P., dos Santos, A. T. L., Fonseca, V. J. A., de Freitas, M. A., Silva, F. D. S., Lopes, L. A., Araújo, N. M. S., Sousa, D. O. B., Silva, R. G. G., Neto, J. X. D. S., et al. (2025) · Current Microbiology · doi:10.1007/s00284-025-04133-0 · Cited by 8
Alves, D. D. N., Melo, A. K. V., Alves, A. F., de Araújo, M. R. C., Araújo, R. D. S., & de Castro, R. D. (2022) · Clinical Oral Investigations · doi:10.1007/s00784-022-04450-9 · Cited by 7
Structure-based drug design of multi-targeting inhibitors of human pathogen fungi
Sakita, K. M., Rodrigues-Vendramini, F. A. V., Svidzinski, T. I. E., Felipe, M. S. S., Maigret, B., & Kioshima, É. S. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135693 · Cited by 7
Metzner, K., O’Meara, M. J., Halligan, B. S., Wotring, J. W., Sexton, J. Z., & O’Meara, T. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00503-23 · Cited by 7
Chivukula, L. G., & LaJeunesse, D. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00938 · Cited by 7
Jiang, Y., Wang, J.-L., Zhang, H., Tian, X., Liang, Z., Xu, X., Bao, J., & Chen, B. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301826 · Cited by 7
Yang, S., Wan, F., Zhang, M., Lin, H., Hu, L., Zhou, Z., Wang, D., Zhou, A., Ni, L., Guo, J., et al. (2024) · Journal of Fungi · doi:10.3390/jof10060397 · Cited by 6
da Costa, P. C. Q. G., Nogueira, P. L., do Nascimento, Y. M., Sobral, M. V., Silvestre, G. F. G., & de Castro, R. D. (2024) · Brazilian Journal of Biology · doi:10.1590/1519-6984.286419 · Cited by 6
Kulig, K., Rudolphi-Skórska, E., Barbasz, A., Surowiec, M., Wronowska, E., Kowalik, K., Satała, D., Braś, G., Woźnicka, O., Karnas, E., et al. (2025) · Microbiology · doi:10.1099/mic.0.001565 · Cited by 6
Heterogeneity of Candida bloodstream isolates in an academic medical center and affiliated hospitals
Scott, N. E., Wash, E., Zajac, C., Erayil, S. E., Kline, S. E., & Selmecki, A. M. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00464-25 · Cited by 6
Zhang, L., Liu, K., Zhou, J., Zhang, Y., Wen, J., He, J., Zheng, Y., Yang, L., Wang, K., & Tian, J. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.06.027 · Cited by 6
A review of bioactive plant compounds against WHO priority fungal pathogens
Calegari-Alves, Y. P., Costa, R. P., Innocente-Alves, C., Soares, G. D. N., Lima, E. S., Saciloto-de-Oliveira, L. R., Alves, L. R., Vainstein, M. H., Beys‐da‐Silva, W. O., & Santi, L. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107930 · Cited by 7
Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives
Kantroo, H. A., Mubarak, M. M., & Ahmad, Z. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108797 · Cited by 6
The PP2A Catalytic Subunit PPH21 Regulates Biofilm Formation and Drug Resistance of Candida albicans
Shen, J., Li, Y., & Miao, H. (2025) · Microorganisms · doi:10.3390/microorganisms13092093 · Cited by 6
Li, S., Shen, Z., Wang, S., Peng, Y., & Qi, W. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1663099 · Cited by 6
Pariano, M., Puccetti, M., Fabi, C., Nunzi, E., Balucchi, S., Perioli, L., Ricci, M., Giovagnoli, S., Garaci, E., & Romani, L. R. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2569831 · Cited by 6
Halliday, C. L., Alguacil-Cuéllar, L., Chen, S. C. ‐., & Alastruey‐Izquierdo, A. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.10.008 · Cited by 7
Generation of antifungals to combat drug resistance using language models and diffusion models
Wang, Y., Dong, Y., Zheng, Y., Xu, L., Song, M., Chen, J., Zhang, K., Shen, T., Zhao, W., Lou, H., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.046 · Cited by 6
One-Pot Synthesis of Triazolo[5,5]-Fused Heterocycles via Heteroaryl Diazonium Salts
Li, M., Dong, Y., Gao, Q., Liu, Y., Yang, H., Cheng, G., Han, J., Huang, W., Xie, J., & Tang, Y. (2025) · JACS Au · doi:10.1021/jacsau.5c01142 · Cited by 6
Zhang, R. Z., Zhang, R. X., Wang, S., Xu, C., Guan, W., & Wang, M. (2021) · Angewandte Chemie · doi:10.1002/ange.202110749 · Cited by 6
Loh, J. T., Teo, J. K. H., Kannan, S., Verma, C. S., Lim, H. H., & Lam, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071780 · Cited by 6
Hassan, F. F., Mushrif, M. H., & Suleiman, A. A. (2024) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-024-00464-3 · Cited by 6
The synergistic effect of photodynamic and sonodynamic inactivation against Candida albicans biofilm
Guimarães, G. G., Alves, F., Gonçalves, I. S., Carvalho, I. S. E., Ayala, E. T. P., Pratavieira, S., & Bagnato, V. S. (2024) · Journal of Biophotonics · doi:10.1002/jbio.202400190 · Cited by 6
Kannan, K. P., & Girija, A. S. S. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01469-w · Cited by 6
Önal, P., Aygün, D., Apaydın, G., Eren, B. A., Kes, G., Aygün, F., Zübarioğlu, T., Beşer, Ö. F., Ocak, S., Yazgan, Z., et al. (2024) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmae015 · Cited by 6
Transdermal delivery of amphotericin B using deep eutectic solvents for antifungal therapy
Xie, B., Jiang, Q., Zhu, F., Lai, Y., Zhao, Y., He, W., & Yang, P. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110508 · Cited by 6
Kumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 6
Baicalin promotes β-1,3-glucan exposure in Candida albicans and enhances macrophage response
Pan, Y., Shi, Z., Wang, Y., Chen, F., Yang, Y., Ma, K., & Li, W. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1487173 · Cited by 6
Anti-biofilm effect of clove oil against Candida albicans: A systematic review
Sangeeta, J. P., Aishwarya, O. B., Omkar, D. B., & Madhura, N. B. (2024) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_225_24 · Cited by 6
Geremia, N., Bragato, B., Giovagnorio, F., Zuglian, G., Brugnaro, P., Solinas, M. L., Stano, P., Panese, S., & Parisi, S. G. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf044 · Cited by 6
Puumala, E., Zaslaver, O., Chen, A., Duncan, D., Fogal, M., Shapiro, R. S., Mazhab‐Jafari, M. T., Whitesell, L. J., Montenegro-Burke, J. R., Robbins, N., et al. (2022) · mBio · doi:10.1128/mbio.02730-22 · Cited by 8
Self-citationDomfeh, S. A., Kyeremeh, G., & Belifini, M. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/6162532 · Cited by 6
Feng, W., Yang, J., Ma, Y., Zhang, L., Yin, R., Qiao, Z., Ji, Y., & Zhou, Y. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00961-z · Cited by 6
Identification of novel inhibitors against Med15a KIX domain of Candida glabrata
Waseem, M., Das, S., Mondal, D., Jain, M., Thakur, J. K., & Subbarao, N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126720 · Cited by 6
Sztafrowski, D., Muraszko, J., Jasiura, A., Bryk, P., Urbanek, A. K., & Krasowska, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291438 · Cited by 6
Design, Synthesis, and Biological Evaluation of N′-Phenylhydrazides as Potential Antifungal Agents
Zhu, P., Zheng, J., Yan, J., Li, Z., Li, X., & Geng, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015120 · Cited by 6
Metadata
- Authors
- Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Cowen, Leah E.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-05-22
- Volume
- 121
- Issue
- 6
- Pages
- 3390-3411
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- PMC
- PMC8519031
- OpenAlex
- W3026958586
- Cited by
- 801
- References
- 237
- Citations by year
- 2026: 109 · 2025: 192 · 2024: 168 · 2023: 133 · 2022: 132 · 2021: 63 · 2020: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canadian Institutes of Health Research (FDN-154288)
- National Institute of Allergy and Infectious Diseases (1R01AI127375-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- antifungal resistance, Candida albicans, Candida auris, Candida glabrata, invasive candidiasis, antifungal agents, molecular mechanisms of resistance, combination antifungal therapy, fungal virulence factors, emerging fungal pathogens
- MeSH terms
- Drug Development, Animals, Antifungal Agents, Candida, Candida albicans, Drug Therapy, Combination, Humans, Mycoses, Virulence, Molecular Structure, Signal Transduction, Drug Resistance, Fungal, Candida glabrata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
